UNSPSC 51161550: Ontazolast

This classification denotes an anti-asthmatic agent with the molecular formula C21H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8P8TW6B25I, chemically known as 2-benzoxazolamine, n-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (s)- but generally known as ontazolast, which bears US NIH Compound Identifier 71458. European Medicines Agency schedules Ontazolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09446MIG.

UNSPSC 51161550 Ontazolast is a Commodity code covering pharmaceutical active ingredients and finished-dose products sourced through cooperative purchasing agreements that state and local government health systems use to supply clinical and institutional facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer under this code, soliciting generic multi-source pharmaceuticals and over-the-counter products through an RFP posted January 20, 2026. MMCAP's cooperative purchasing structure serves multiple state and local government entities across participating jurisdictions, including Minnesota and Oregon, through an established network of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencara, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). Vendors must comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements; maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place; and carry comprehensive insurance including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Pricing submissions are weighted heavily toward price competitiveness (75 percent) and fixed pricing (10 percent), with administrative fees at 3 percent on all contract purchases.

MMCAP's RFP closes March 26, 2026, with a February 18, 2026 cutoff for vendor questions; awarded vendors will be identified to wholesalers by May 15, 2026, and resulting agreements become effective July 1, 2026. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028. The solicitation contemplates sole, dual, or multi-award outcomes based on therapeutic considerations, product availability, and member-specific needs. No specific award values, budget ranges, or set-aside designations are disclosed in the available RFP materials. Vendors must submit detailed product information including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations through the ePro procurement system, with pricing and product data in Excel format converted to CSV and supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us.